Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AEROLATE SR vs NASAREL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins, leukotrienes, and cytokines, thereby reducing nasal inflammation.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Seasonal and perennial allergic rhinitis,Nonallergic rhinitis,Nasal polyps (off-label)
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
2 sprays (50 mcg/spray) in each nostril once or twice daily; maximum 8 sprays/day.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Terminal half-life approximately 15-25 minutes for flunisolide (the active ingredient in NASAREL) in the systemic circulation after intranasal administration. Clinically, the half-life is short, reducing the risk of systemic accumulation but requiring twice-daily dosing for consistent effect.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Primarily hepatic via CYP3A4 isoform; undergoes extensive first-pass metabolism.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <30% of dose. Fecal elimination minimal (<5%).
55–65% bound to plasma proteins, primarily albumin.
Approximately 40-50% bound to plasma proteins, primarily albumin.
0.4–0.6 L/kg, indicating distribution into total body water.
Volume of distribution is approximately 1.4–2.0 L/kg after IV administration, indicating extensive tissue distribution. For intranasal use, the Vd is not directly applicable but reflects systemic exposure if absorbed.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
Intranasal: Systemic bioavailability is approximately 21% (range 10-50%) due to first-pass metabolism. Oral bioavailability is <1% due to extensive hepatic first-pass effect. The drug is administered intranasally for local effect with low systemic exposure.
No dose adjustment required for renal impairment.
No dose adjustment required for renal impairment.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
No dose adjustment required for hepatic impairment.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Children 6-11 years: 1 spray in each nostril once daily; maximum 4 sprays/day. Children ≥12 years: same as adult.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No specific dose adjustment; use lowest effective dose.
No FDA black box warning exists for this drug.
None
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
May cause epistaxis, nasal septal perforation, or nasal mucosal ulceration,Potential for systemic corticosteroid effects with prolonged use,May suppress hypothalamic-pituitary-adrenal (HPA) axis, especially at higher doses,Increased susceptibility to infections; avoid in active untreated infections,Use with caution in patients with tuberculosis, ocular herpes simplex, or untreated fungal/bacterial infections
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Hypersensitivity to flunisolide or any component of the formulation,Untreated localized nasal infections (e.g., bacterial, fungal, viral)
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
No significant food interactions known. May take without regard to meals. Avoid consuming grapefruit or grapefruit juice as it may increase systemic exposure (weak CYP3A4 interaction).
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
FDA Pregnancy Category C: In animal studies, corticosteroids have been shown to be teratogenic at high doses. No adequate and well-controlled studies in pregnant women. Nasarel (flunisolide) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Theoretical risk of cleft palate; avoid systemic absorption by using minimal effective dose. Second and third trimesters: No specific risks reported; monitor for fetal adrenal suppression if used chronically at high doses.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
It is not known whether flunisolide is excreted in human milk. Because many corticosteroids are excreted in human milk, caution should be exercised when Nasarel is administered to a nursing woman. M/P ratio not available. Use with caution; consider using lowest effective dose and monitoring infant for signs of adrenal suppression.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
No specific dose adjustments required due to pharmacokinetic changes in pregnancy. Use lowest effective dose to minimize systemic absorption. No change in hepatic metabolism or renal clearance expected for intranasal flunisolide.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
For best results, advise patients to blow nose gently before use. Avoid spraying directly onto nasal septum to reduce risk of epistaxis and septal perforation. Tilt head forward slightly and spray away from septum. Priming pump (6 sprays or until fine mist appears) is essential if not used for >7 days. Monitor nasal mucosal integrity during long-term use. May cause transient stinging or burning; consider co-administration with saline spray if irritation persists.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
Use exactly as prescribed; do not exceed recommended dose.,Shake bottle gently before each use.,Prime pump by spraying 6 times into air if new or not used for 7 or more days.,Blow nose to clear nasal passages before administration.,Insert nozzle into nostril, tilt head slightly forward, and spray away from the nasal septum.,Avoid spraying directly onto the nasal septum.,Rinse nozzle with warm water after each use and replace cap tightly.,Do not share the medication with others.,If using other nasal sprays, use them at different times (separated by 10-15 minutes).,Contact doctor if symptoms do not improve after 3 weeks or if nasal bleeding occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AEROLATE SR vs NASAREL, answered by our medical review team.
AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. NASAREL is a Intranasal Corticosteroid that works by Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins, leukotrienes, and cytokines, thereby reducing nasal inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AEROLATE SR and NASAREL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. The standard adult dose of NASAREL is: 2 sprays (50 mcg/spray) in each nostril once or twice daily; maximum 8 sprays/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AEROLATE SR and NASAREL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. NASAREL is classified as Category C. FDA Pregnancy Category C: In animal studies, corticosteroids have been shown to be teratogenic at high doses. No adequate and well-controlled studies in pregnant women. Nasarel (fl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.